文献速递鼻科小儿耳鼻咽喉

奥马珠单抗联合过敏原免疫治疗对比单用免疫治疗过敏性疾病:随机对照试验的荟萃分析

Combination of omalizumab with allergen immunotherapy versus immunotherapy alone for allergic diseases: A meta-analysis of randomized controlled trials.
PubMed 文献 · Int Forum Allergy Rhinol · 2023-09-16

该荟萃分析纳入11项随机对照试验、共901例患者,比较奥马珠单抗联合过敏原免疫治疗(AIT)与单用AIT的疗效与安全性。联合治疗显著提高达到目标维持剂量和持续无反应的患者比例,并显著减少严重全身性不良事件。

要点

  • 联合治疗较单用AIT显著提高达到目标维持剂量的患者数(OR=2.43)。
  • 联合治疗较单用AIT显著提高对过敏原的持续无反应(OR=6.77)。
  • 联合治疗较单用AIT显著减少严重全身性不良事件(OR=0.32)。

核心结论

  • 奥马珠单抗联合AIT可通过提高目标维持剂量和持续无反应、减少严重全身性不良事件,显著增强AIT的疗效与安全性。

研究设计与样本

  • 荟萃分析,检索MEDLINE/PubMed、Embase、Scopus和Cochrane Library数据库,纳入11项报告奥马珠单抗联合AIT对比单用AIT结局的随机对照试验,共涉及901例患者,采用随机效应模型估计结局及95%CI。

主要发现

  • 联合治疗组达到目标维持剂量的患者数显著多于单用AIT组(OR=2.43;95%CI:1.33-4.44;p=0.004;I²=35%)。
  • 联合治疗组对过敏原的持续无反应显著优于单用AIT组(OR=6.77;95%CI:2.10-21.80;p=0.001;I²=36%)。
  • 联合治疗组严重全身性不良事件发生次数显著少于单用AIT组(OR=0.32;95%CI:0.18-0.59;p=0.0003;I²=0%)。
  • 症状严重程度评分的改善(MD=-0.26)、急救药物每日平均评分(MD=-0.14)以及AIT中接受肾上腺素治疗的患者数(OR=0.20)在联合治疗组均较单用AIT组更明显。

临床怎么用

  • 原文结论指出,奥马珠单抗联合AIT可通过提高目标维持剂量和持续无反应、减少严重全身性不良事件,显著增强AIT的疗效与安全性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Allergen immunotherapy (AIT)-associated adverse events (AEs) limit its usage in the management of allergic diseases. The monoclonal anti-IgE antibody (omalizumab) and AIT have complementary actions. However, no consensus has been reached on whether their combination could exert superior efficacy and safety. OBJECTIVE: To evaluate whether the combination of AIT with omalizumab is superior to AIT alone in treating allergic diseases. METHODS: The MEDLINE/PubMed, Embase, Scopus and Cochrane Library databases were searched to identify randomized control trials (RCTs) reporting the outcomes of omalizumab combined with AIT (omalizumab + AIT) versus AIT alone. A random-effect model was established to estimate outcomes with a 95% confidence interval (CI). RESULTS: A total of 11 eligible RCTs (involving 901 patients) were screened out for the meta-analysis. According to a pooled analysis, omalizumab + AIT significantly increased the number of patients achieving the target maintenance dose (TMD) and sustained unresponsiveness (SU) to allergens (odds ratio [OR] = 2.43; 95% CI: 1.33-4.44; p = 0.004; I2 = 35%, and OR = 6.77; 95% CI: 2.10-21.80; p = 0.001; I2 = 36%, respectively). Similarly, individuals receiving the combination therapy reported significantly fewer episodes of severe systemic AEs than AIT alone (OR = 0.32; 95% CI: 0.18-0.59; p = 0.0003; I2 = 0%). Meanwhile, the improvements in symptom severity score (mean difference [MD] = -0.26), rescue medication daily means score (MD = -0.14), and number of patients consuming epinephrine in AIT (OR = 0.20) were all more evident than those in AIT alone. CONCLUSION: Omalizumab + AIT can significantly enhance the efficacy and safety of AIT by increasing TMD and SU to allergens, while decreasing severe systemic AEs.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Zhang YY, Zhang M, Zhang JQ, et al. Combination of omalizumab with allergen immunotherapy versus immunotherapy alone for allergic diseases: A meta-analysis of randomized controlled trials. Int Forum Allergy Rhinol. 2023. PMID: 37715592. doi:10.1002/alr.23268

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。